Biophytis S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BPTSY research report →
About the company
Biophytis S. A. is a clinical-stage biotechnology firm dedicated to developing therapeutic interventions that slow the degenerative processes associated with age and improve functional outcomes for patients.
- CEO
- Stanislas Veillet
- IPO
- 2021
- Employees
- 22
- HQ
- Paris, FR
Price Chart
- Market Cap
- $105.22K
- P/E
- -0.01
- P/S
- 0.00
- P/B
- -0.01
- EV/EBITDA
- -1.23
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 153.48%
- ROIC
- -2242.74%
- Revenue
- $0 · 0.00%
- Net Income
- $-10,379,000 · 39.04%
- EPS
- $-2.00 · 98.41%
- Op Income
- $-8,500,000
- FCF YoY
- 33.99%
- 52W High
- $3.36
- 52W Low
- $0.00
- 50D MA
- $0.32
- 200D MA
- $1.48
- Beta
- 0.90
- Avg Volume
- 90
Get TickerSpark's AI analysis on BPTSY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BPTSY coverage
Recent articles, reports, and earnings notes.
No research on BPTSY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BPTSY report →Similar companies
Peers in the same neighborhood.